Mycoplasma Testing

REPORT HIGHLIGHTS

Global Mycoplasma Testing Market to Reach US$2.3 Billion by 2032

The global market for Mycoplasma Testing estimated at US$1.1 Billion in the year 2025, is expected to reach US$2.3 Billion by 2032, growing at a CAGR of 11.2% over the analysis period 2025-2032. Instruments Component, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Kits & Reagents Component segment is estimated at 8.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$336.6 Million While China is Forecast to Grow at 15.9% CAGR

The Mycoplasma Testing market in the U.S. is estimated at US$336.6 Million in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$608.8 Million by the year 2032 trailing a CAGR of 15.9% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.

Global Mycoplasma Testing Market – Key Trends & Drivers Summarized

What Is Mycoplasma Testing and Why Is It Essential in Biopharmaceuticals and Cell Cultures?

Mycoplasma testing refers to the detection of mycoplasma contamination in cell cultures, biopharmaceutical products, and vaccines. Mycoplasmas are a group of bacteria that lack a cell wall and can cause contamination in cell cultures used in biopharmaceutical production. Due to their small size and flexibility, they can pass through conventional filters and contaminate biotechnological processes without detection, compromising product safety and efficacy. Mycoplasma contamination can lead to alterations in cell physiology, inaccurate experimental results, and product recalls, making routine testing essential in laboratories, pharmaceutical companies, and biopharmaceutical production facilities. Testing for mycoplasma is critical for ensuring compliance with regulatory standards and maintaining the integrity of cell-based products used in medical treatments and research.

How Are Technological Advances Shaping Mycoplasma Testing Methods?

Technological innovations are significantly improving the accuracy, speed, and reliability of mycoplasma testing. Traditionally, mycoplasma detection was performed using culture-based methods, which are time-consuming and labor-intensive, taking weeks to yield results. However, advancements in molecular diagnostics, such as polymerase chain reaction (PCR) and real-time PCR (qPCR), have revolutionized mycoplasma testing by enabling faster, more sensitive, and specific detection of contamination. Additionally, nucleic acid amplification techniques (NAATs) and next-generation sequencing (NGS) technologies are further enhancing detection capabilities, allowing for the identification of a broader range of mycoplasma species. Automated testing platforms are also reducing the time and labor required for routine testing, making it easier for laboratories and production facilities to ensure contamination-free environments in real-time.

How Are Regulatory Requirements and Industry Standards Impacting the Demand for Mycoplasma Testing?

Stringent regulatory requirements in biopharmaceutical production and the increasing demand for safe and effective biotechnological products are driving the demand for mycoplasma testing. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate routine mycoplasma testing for cell-based products, biologics, and vaccines to ensure product safety and prevent contamination. Compliance with these regulations is critical for pharmaceutical companies to maintain product approval and avoid costly delays or recalls. The growing biopharmaceutical industry, along with the expansion of contract research organizations (CROs) and contract manufacturing organizations (CMOs), is also pushing the adoption of faster and more reliable mycoplasma testing methods. Moreover, with the rise in cell and gene therapies, where contamination risks can significantly affect product viability, the need for stringent testing protocols has become even more essential.

What Are the Key Growth Drivers in the Mycoplasma Testing Market?

The growth in the mycoplasma testing market is driven by several factors, including advancements in molecular diagnostics, increased regulatory scrutiny, and the expansion of biopharmaceutical production. The shift toward faster and more precise testing methods, such as PCR and NGS, is enhancing contamination detection, making these technologies increasingly popular in the industry. The rising prevalence of biologics, vaccines, and cell-based therapies is also contributing to the growing demand for reliable mycoplasma testing, as these products are particularly susceptible to contamination. Additionally, regulatory requirements mandating regular testing of biologics and cell cultures are further pushing the adoption of advanced mycoplasma detection solutions. The growing use of contract research and manufacturing services in the pharmaceutical industry is another driver, as these organizations require robust testing protocols to ensure compliance and product safety. Lastly, the increasing focus on quality control in biotechnological processes is promoting the continuous development of more efficient and automated testing platforms, further accelerating market growth.

SCOPE OF STUDY:

The report analyzes the Mycoplasma Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Instruments Component, Kits & Reagents Component, Services Component); Technology (PCR Technology, ELISA Technology, Direct Assay Technology, Indirect Assay Technology, Microbial Culture Technology, Enzymatic Method Technology); Application (Cell Line Testing Application, Virus Testing Application, End of Production Cells Testing Application, Other Applications); End-Use (Academic Research Institutes End-Use, Cell Banks End-Use, Contract Research Organizations End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• American Type Culture Collection (ATCC)
• Biological Industries Israel Beit Haemek Ltd.
• Biounique Testing Laboratories Inc.
• Charles River Laboratories International, Inc.
• Invivogen
• Lonza Group AG
• Merck KgaA
• Norgen Biotek Corporation
• Promocell GmbH
• Roche Diagnostics (Schweiz) AG
• SGS SA
• Thermo Fisher Scientific, Inc.
• Wuxi Apptec Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more